key: cord-0874322-pbntix4n
authors: Lee, Jungsoon; Liu, Zhuyun; Chen, Wen-Hsiang; Wei, Junfei; Kundu, Rakhi; Adhikari, Rakesh; Rivera, Joanne Altieri; Gillespie, Portia M.; Strych, Ulrich; Zhan, Bin; Hotez, Peter J.; Bottazzi, Maria Elena
title: Process Development and Scale-up Optimization of the SARS-CoV-2 Receptor Binding Domain-Based Vaccine Candidate, RBD219-N1C1
date: 2020-12-30
journal: bioRxiv
DOI: 10.1101/2020.12.30.424829
sha: d9a54e77efe14592f45a3dbe26d395198f091ec9
doc_id: 874322
cord_uid: pbntix4n

A SARS-CoV-2 RBD219-N1C1 (RBD219-N1C1) recombinant protein antigen formulated on Alhydrogel® has recently been shown to elicit a robust neutralizing antibody response against SARS-CoV-2 pseudovirus in mice. The antigen has been produced under current good manufacturing practices (cGMP) and is now in clinical testing. Here, we report on process development and scale-up optimization for upstream fermentation and downstream purification of the antigen. This includes production at the 1 and 5 L scale in the yeast, Pichia pastoris, and the comparison of three different chromatographic purification methods. This culminated in the selection of a process to produce RBD219-N1C1 with a yield of >400 mg per liter of fermentation with >92% purity and >39% target product recovery after purification. In addition, we show the results from analytical studies, including SEC-HPLC, DLS, and an ACE2 receptor binding assay that were performed to characterize the purified proteins to select the best purification process. Finally, we propose an optimized upstream fermentation and downstream purification process that generates quality RBD219-N1C1 protein antigen and is fully scalable at a low cost.

A SARS-CoV-2 RBD219-N1C1 (RBD219-N1C1) recombinant protein antigen formulated on 24 Alhydrogel ® has recently been shown to elicit a robust neutralizing antibody response against 25 SARS-CoV-2 pseudovirus in mice. The antigen has been produced under current good 26 manufacturing practices (cGMP) and is now in clinical testing. Here, we report on process 27 development and scale-up optimization for upstream fermentation and downstream purification 28 of the antigen. This includes production at the 1 and 5 L scale in the yeast, Pichia pastoris, and 29 the comparison of three different chromatographic purification methods. This culminated in the 30 selection of a process to produce RBD219-N1C1 with a yield of >400 mg per liter of 31 fermentation with >92% purity and >39% target product recovery after purification. In addition, 32

we show the results from analytical studies, including SEC-HPLC, DLS, and an ACE2 receptor 33

After the first report of coronavirus disease 2019 in December 2019 [21, 24] , the 40 number of cases is now at 75 million with over 1.6 million deaths worldwide [16] . As of 41

December 2020, two vaccines from Pfizer/BioNTech and Moderna have been approved for 42 emergency use in multiple countries. These frontrunner vaccines represent a new platform, 43 mRNA-based vaccines; while they were produced in record time, they are relatively expensive 44 to manufacture and require transportation and storage at temperatures below -20°C. Such 45 features present formidable challenges to distribute these vaccines to low-and middle-income 46 countries (LMICs). Confounding equity access for COVID-19 vaccines are the still uncertain 47 production and distribution delays or even the quality of other vaccines. This situation could 48 leave LMICs bereft of low-cost COVID-19 vaccines suitable for their modest or depleted 49 health systems [20] . In response, a network of LMIC vaccine developers and manufacturers 50 are accelerating vaccines employing traditional platforms, such as an inactivated virus and 51 recombinant proteins, with several under preclinical and clinical development [9] . These 52 vaccine candidates are less demanding with respect to transport and storage, and often come 53 with a long history of successful production and use for other infectious diseases [15] . 54

Particularly attractive in this aspect are recombinant protein antigens produced through 55 microbial fermentation in yeast. For instance, recombinant Hepatitis B vaccine has been 56 administered to adults and children for decades [13] . 57

The SARS-CoV-2 virus, the pathogen that causes COVID-19, uses its surface spike (S) 58 protein for host cell entry, just like its close relative, SARS-CoV that had caused an outbreak 59 of Severe Acute Respiratory Disease in 2002. The Receptor Binding Domain (RBD) of the S 60 protein binds to a cellular receptor, angiotensin-converting enzyme 2 (ACE2) that mediates 61 membrane fusion during viral entry into the cell [22, 28] . S proteins for both viruses have served 62 as vaccine antigens that could elicit antibodies to prevent virus entry by blocking the binding 63 of RBD to ACE2 [14] , and all the leading COVID-19 vaccines currently in clinical trials, 64

including the mRNA vaccines, use the S protein to elicit immunity [12] . Overwhelmingly, such 65 vaccines protect through their induction of virus-neutralizing antibodies, together with T cell 66 responses [17] . 67

Building on our experience with the RBD of the SARS-CoV spike protein [5,7,4], the 68 SARS-CoV-2 RBD was cloned and expressed in the yeast Pichia pastoris [8] . Yeast has a track 69 record of serving as a host organism for the production of multiple regulatory-approved and 70 prequalified recombinant subunit vaccines, including vaccines for Hepatitis B, Influenza B, 71 human papillomavirus, as well as for Diphtheria and Tetanus [1, 19] . Eukaryotic expression in 72 yeast shows advantages over the prokaryote, Escherichia coli, with respect to the production 73 of recombinant protein vaccines. Proper protein folding, disulfide bridge formation, post-74 translational modifications, and secretory cleavage are better supported in yeast, while also 75 allowing for robust production with low costs and full scalability, features that distinguish this 76 platform from other eukaryotic systems, such as insect cells, mammalian cells, and plants. 77

The RBD219-N1C1 antigen is derived from residues 332-549 of the SARS-CoV-2 78 RBD with a single mutation of a free cysteine residue (Cys538) to alanine to prevent 79 intermolecular disulfide bond formation and therefore unwanted oligomerization during 80 process development [8] . In addition, N1 refers to the deletion of Asn331 to avoid 81 hyperglycosylation observed in previous studies with the SARS-CoV RBD219-N1 antigen [5] . 82

In initial studies, the RBD219-N1C1 recombinant protein antigen adjuvanted with Alhydrogel ® 83 has been shown to elicit a robust neutralizing antibody response against SARS-CoV-2 84 pseudovirus in mice [25] . 85

With any COVID-19 vaccine candidate, the ability to produce billions of doses 86 efficiently is crucial to satisfy the potential global vaccine demand. We, therefore, have been 87 developing and optimizing a scalable production process of the RBD219-N1C1 vaccine 88 candidate at low cost to support its technology transfer. Initial fermentation runs scouting for 89 growth media, induction time, and glycerol fed-batch conditions were executed in a 1 L 90 bioreactor and resulted in a ~10-fold increase in RBD219-N1C1 expression levels. Further 91 scale-up experiments in a 5 L bioreactor established reproducibility of the selected conditions. 92

Simultaneously, a purification scheme was developed based on the process used for the 70% 93 homologous SARS-CoV RBD antigen [4] , and further optimized to allow full scalability and 94 lower the cost. Taking into consideration, yield, purity, functionality, and removal of host cell 95 contaminants, we have developed an optimized fermentation at the 5 L scale and purification 96 (Process-2) suitable for production and manufacturing of a high-yield (and therefore 97 potentially low-cost) COVID-19 vaccine antigen candidate. The developed process has already 98 been transferred to an industrial vaccine manufacturer in India and is currently undergoing 99 further production maturity while the vaccine candidate is in a Phase 1/2 clinical trial. 100 101

To generate a research cell bank (RCB), P. pastoris X33 strain was transformed with 104 expression plasmid pPICZαA containing RBD219-N1C1 coding DNA, and one transformed 105 colony with high expression of recombinant RBD219-N1C1 protein [8] was selected and 106 streaked on YPD plates containing 100 μg/mL Zeocin to make single colonies. The plates were 107 incubated at 30 °C for approximately 3 days until single colonies were observed. Subsequently, 108 200 mL plant-derived phytone YPD medium was inoculated with a single colony from the 109 respective plate and incubated at 30 °C with constant shaking (225 RPM) until the OD600 110 reached 9.3. Finally, the cell culture was mixed with plant-derived glycerol to a final 111 concentration of 20% and aseptically aliquoted (1 mL each) into 1.2 mL cryovials. For long-112 term storage, the cryovials were stored at −80 °C. 113

One vial of the SARS-CoV-2 RBD219-N1C1 RCB was used to inoculate 1 L BMG (Buffered 115

Minimal Glycerol) medium in a 2 L shake flask. The shake flask culture was grown at 30°C 116 and 225 rpm until an OD600 of 5 -10. For 1 L fermentations, this seed culture was inoculated 117 into 0.4 L of sterile basal-salt medium (BSM), pH 5.0 (BSM: 18.2 g/L potassium sulfate, 14.9 118 g/L magnesium sulfate heptahydrate, 4.13 g/L potassium hydroxide, 0.93 g/L calcium sulfate 119 dehydrate, 26.7 mL/L of 85% phosphoric acid, and 40 g/L glycerol) or low-salt medium 120 (LSM), pH 5.0 (LSM: 4.55 g/L potassium sulfate, 3.73 g/L magnesium sulfate heptahydrate, 121 1.03 g/L potassium hydroxide, 0.23 g/L calcium sulfate dehydrate, 10.9 mL/L of 85% 122 phosphoric, and 40 g/L glycerol) to a starting cell density (OD600) of 0.5. Fermentation was 123 conducted using a Biostat Qplus Bioreactor with a 1 L vessel (Sartorius Stedim, Guxhagen, 124 Germany). For 5 L runs, the seed culture was inoculated into 2.5 L of LSM, and fermentation 125 was conducted in a CelliGen 310 Bioreactor with a 7.5 L vessel (Eppendorf, New York, USA), 126 controlled by the Eppendorf Bio Command software. Cell expansion was continued at 30 °C 127 with a dissolved oxygen (DO) set point of 30%. Following the DO spike, a fed-batch was 128 initiated with 50% glycerol at a feed rate of 15 mL/L/hr for 6 hours. During the last hour of the 129 fed-batch phase, pH and temperature were increased to the desired value (pH=6.5, 130 temperature=25°C). When a glycerol fed-batch was not included in the fermentation process, 131 the pH and temperature were adjusted to the desired value during the first hour of induction. 132

After the fed-batch phase, methanol induction was initiated; the total induction time was 133 approximately 68-72 hours. Biomass was removed by centrifugation at 12,227 x g for 30 134 minutes at 4 °C before the supernatant was filtered through 0.45 µm PES filters stored at -80 135 °C until purification. 136

The FS was removed from -80 °C and thawed at 22 °C for 4-6 hours. Three purification 138 processes were performed with 1 L FS aliquots ( Figure 1B ). In Process-1, the RBD219-N1C1 139 protein was captured from the FS using hydrophobic interaction chromatography (HIC), 140 concentrated by ultrafiltration/diafiltration (UFDF), and polished using size exclusion 141 chromatography (SEC). In Process-2, the RBD219-N1C1 protein was captured using HIC, 142 buffer-exchanged (UFDF), and polished using anion exchange chromatography (AEX). 143

Finally, in Process-3, the FS was buffer-exchanged using UFDF before the target protein was 144 captured using cation exchange chromatography (CEX), buffer-exchanged (UFDF), and 145 polished using AEX. 146

Two types of devices were used for UFDF, a centrifugal concentrator, and a flat sheet membrane area throughout the entire process with an average TMP of ~8 psi. For the UFDF-161 2, the CEX elution pool was concentrated 4-fold followed by diafiltration with 4 diavolumes 162 of 25 mM Tris-HCl pH 7.2 and 5 mM NaCl using the Pellicon XL Cassette as described for 163

Process-2. 164

In Processes 1 and 2, HIC was used to capture RBD219-N1C1 proteins from the FS. 

Five mL of the concentrated HIC elution pool was loaded on a HiLoad 16/600 Superdex 75 173 prep-grade column (Cytiva, Marlborough, USA), pre-equilibrated with 20 mM Tris-HCl pH 174 7.5 and 150 mM NaCl, and eluted at a flow rate of 1 mL/min. The SEC elution pool was 175 aseptically filtered using 0.2 µm PES in a biosafety cabinet and stored at -80 °C until usage. 176

In Process-3, RBD219-N1C1 was captured using CEX. The Pellicon 2 retentate pool in 20 mM 178 sodium citrate pH 4.2 and 10 mM NaCl was loaded on a 50 mL CM Sepharose Fast Flow 179 column (2.6 cm diameter and 9.3 cm bed height) at 10 mL/min flow rate. The column was 180 washed with 20 mM sodium citrate pH 4.2 and 10 mM NaCl. Bound proteins were eluted in 181 20 mM sodium citrate pH 6.6 and 10 mM NaCl. 182

In Processes 2 and 3, RBD219-N1C1 was polished using a negative capture AEX. The 183

Pellicon XL retentate pool was loaded on a HiPrep Q Sepharose XL 16/10 column (Cytiva, 184

Marlborough, USA) that was pre-equilibrated with 20 mM Tris-HCl pH 7.5 and 100 mM NaCl 185

for Process-2, and 25 mM Tris-HCl pH 7.2 and 5 mM NaCl for Process-3. The flowthrough 186 from AEX was collected, aseptically filtered using 0.2 µm PES filters in a biosafety cabinet, 187 and stored at -80 °C until usage. NaCl (95 mM) was added to the final purified proteins from 188

Process-3 prior to storage in 25 mM Tris-HCl pH 7.2 and 100 mM NaCl. 189

In-process samples taken at each purification step were loaded on either 14% Tris-glycine gels 191 or 4-12% Bis-Tris gels to determine the concentration and purity of the various RBD219-N1C1 192 samples. Purified RBD219-N1C1 proteins of known concentrations were used as standards. 

The binding of RBD219-N1C1 to recombinant human angiotensin-converting enzyme 2 244 (ACE2) was evaluated using an ELISA procedure described previously [8] . In short, 96-well 245 ELISA plates were coated with 100 µL 2 µg/mL RBD219-N1C1 overnight at 4°C followed by 246 blocking with PBST/0.1% BSA. 100 µL serially-diluted ACE2-hFc (LakePharma, San Carlos, 247 USA; Cat # 46672) was added to the wells and incubated at room temperature for 2 hours and 248 the binding was detected by adding 100 µL 1:10,000 diluted HRP conjugated anti-human IgG 249 antibodies (GenScript, Piscataway, USA; Cat# A00166) with a 1-hour incubation period at 250 room temperature. Finally, 100 µL TMB substrate was provided to each well to react with HRP 251 and the reaction was terminated with 100 µL 1M HCl. Absorbance at 450 nm was measured 252 using an EPOCH 2 microplate reader (BioTek, Winooski, USA). 253

When basal-salt medium (BSM) and low-salt medium (LSM) were compared for the 257 production of the RBD219-N1C1 protein, no differences were observed in the growth profiles 258 and the final biomass. However, the salt concentration appeared to have a significant effect on 259 the yield. The yield of the RBD219-N1C1 protein using BSM was only 52 mg/L while using 260 LSM 237 mg/L were achieved ( Table 1 , Runs 1 and 2). Therefore, LSM was used for the 261 further development of the fermentation process. 262

The baseline fermentation process consisted of two phases: a glycerol-batch phase and 263 a methanol fed-batch phase. In glycerol-batch mode, LSM contained 40 g/L of glycerol. At the 264 time of glycerol depletion, the initial induction biomass was 110 ± 10 g/L (WCW). In this 265 study, a glycerol fed-batch phase was then added before methanol induction to test the 266 efficiency of protein expression based on the initial induction biomass. After a 6-hour glycerol 267 fed-batch phase, the initial induction biomass doubled to 210 ± 20 g/L (WCW). The methanol 268 feed strategies were kept the same. At harvest, the final OD600 and the biomass were determined 269 to be 260 AU and 417 g/L, respectively. By adding the glycerol fed-batch, the yield of 270 RBD219-N1C1 was increased about 120% to 533 mg/L (Table 1, Run 3) . 271

The fermentation process with six hours of glycerol feed was then scaled up from 1 L to 5 L to 273 test scalability and reproducibility (Table 1 , Run 4). The induction time was extended to 87 274 hours until biomass started to drop. This suggested that the cells were no longer actively 275 dividing. Since excessive methanol feeding may lead to cell death thus leading to a loss of 276 protein yield, it was decided to stop the methanol feeding after 87 hours of induction. The peak 277 yield of RBD219-N1C1 was 449 ± 8 mg/L at 70 hours after induction (Day 3), after which the 278 yield slightly dropped to 408 ± 9 mg/L at 87 hours after induction. 279

The fermentation process without the 6-hour glycerol fed-batch phase was also scaled up from 280 1 to 5 L for comparison (Table 1 , Run 5). After 70 ± 2 hours of induction, the yield of RBD219-281 N1C1 reached 479 ± 15 mg/L (a 128% increase compared to the 1 L scale). This yield was 282 close to the yield of the fermentation run with the 6-hour glycerol fed-batch phase ( Table 1,  283 Run 4). Since there was no significant increase in yield by the glycerol fed-batch at 5 L scale, 284 we decided to proceed without this step ( Figure 1A ). To establish reproducibility, this 285 fermentation process ( Figure 1A 

In parallel with the fermentation optimization, three different processes were performed to 293 purify RBD219-N1C1 from the FS ( Figure 1B) . Process-1 was developed by adapting the 294 purification method of our SARS-CoV-RBD219-N1 antigen that shares 70% homology with 295 the SARS-CoV-2 RBD [8,4,27]. In this process, the target protein was captured by HIC using 296 a butyl HP column with 1 M ammonium sulfate salt for the binding. After the HIC, 67% of the 297 target protein was recovered and purity significantly improved from 85.6% in the FS to 97.6% 298 ( Figure 3A ). The target protein was concentrated using Amicon centrifugal concentrators and 299 further polished by SEC using a Superdex 75 column. The SEC elution pool was then diluted 300 to 2 mg/mL for storage. Overall, the final yield of the target protein using Process-1 was 188.8 301 mg/L FS (Figure 3A) , representing a recovery of 50% with a purity of 98.3%. This is similar 302 to the overall recovery of 52% and the purity of 98.5% shown with the SARS-CoV-RBD219-303

Although Process-1 is sufficient and proven to produce proteins at high yield and purity 305 at the laboratory scale, up to 10 L [4], there are considerations to be made with respect to 306 scaling-up manufacture. Both HIC and SEC are costly steps due to their low binding and 307 process capacities, requiring large resin volumes and long processing times. Therefore, we 308 explored two alternative processes utilizing IEX, favored in the biopharmaceutical industry 309 due to its low cost and high scalability. 310

In Process-2, the capture step was unchanged. After the UFDF step to concentrate and 311 exchange buffer, the target protein was polished by a negative capture using AEX instead of 312 SEC ( Figure 1B) . While the RBD219-N1C1 did not bind to the Q XL column, non-specific 313

HCPs were bound to the column and removed effectively. The step recovery during AEX was 314 78%, which is lower than the 89% of the step recovery seen from SEC in Process-1. The final 315 purity of the purified protein from Process-2 was 95.1%, which is lower than the 98.3% purity 316 seen in Process-1 but still highly pure. However, the overall recovery in Process-2 was only 317 39%, much lower than the 50% for Process-1. This is due to the lower recovery during HIC, 318 45%, that lags the 67% recovery seen for the equivalent step in Process-1. This lower recovery 319 may offer the opportunity for improvement, but overall, it is fair to conclude that AEX can 320 successfully replace SEC for the polishing step. 321

In Process-3, we further optimized Process-2 to utilize CEX for the capture step instead 322 of HIC. After the first UFDF step (UFDF-1) to concentrate and buffer exchange the FS, 323 RBD219-N1C1 was captured using a CM FF column followed by a second UFDF step (UFDF-324 2) and a polishing step using negative AEX capture ( Figure 1B) . The additional UFDF-1 step 325 required prior to CEX increased processing time compared to Processes 1 and 2. Although the 326 step recovery from CEX was 65%, very similar to the 67% seen after the HIC in Process-1, the 327 purity was only 83% after CEX which is significantly lower than the purity (97.6% and 95.2% 328 from Process-1 and -2, respectively) after HIC ( Figure 3C ). Purity was improved significantly 329 by 9.5% after the polishing step, resulting in an overall purity of 92.5%, which is lower than 330 the 98.3% and 95.1% seen in Processes 1 and 2, respectively. 331

To summarize, HIC showed a superior performance to remove non-specific host 332 proteins and, hence, resulted in >95% purity after the capture step, which is even higher purity 333 than 92.5% purity seen in the final protein product from Process-3. This favored HIC over CEX 334 although its only drawback is the cost. HIC has no limitation on scale-up. On the other hand, 335 both AEX and SEC showed very similar performance during the polishing step. However, 336 while AEX is cost-effective chromatography with full scalability, SEC is expensive and has 337 limitations in scale-up. This reasons us to favor Process-2 employing HIC and AXE for the 338 capture and the polishing step, respectively. Before we urge to conclude that Process-2 is the 339 best process to produce RBD219-N1C1, we characterized and compared the purified protein 340 from Process-2 and two other processes for integrity, size estimation, impurity contents, and 341 functionality. 342

The purified proteins from all processes were characterized for integrity by Western blot, SEC-344 HPLC, and DLS. When 5 µg of purified protein were analyzed by SDS-PAGE followed by 345

Coomassie Blue staining, a single band was seen at ~28 kDa under reducing and ~25 kDa under 346 non-reducing conditions ( Figure 4A ). Western blot analysis using a monoclonal antibody 347 against SARS-CoV-2 Spike protein under a non-reducing SDS-PAGE indicating that the ~25 348 kDa band is indeed derived from the SARS-CoV-2 Spike protein ( Figure 4B ). An additional 349 band at ~50 kDa was detected in the protein from Process-3, likely representing a dimer. 350

Dimerization through free cysteine residues had also been reported for SARS-CoV-RBD219-351 N1, and therefore the free cysteine (C538) was mutated to alanine in RBD219-N1C1 [8] . 352

Although RBD219-N1C1 theoretically lacks free cysteine residues, we observed some dimers 353 during the fermentation that were removed during purification. Therefore, Process-3 appears 354 to be less efficient at removing dimeric RBD219-N1C1 than the other processes. 355 SEC-HPLC with 50 µg of the purified protein preparations indicated that all three 356 proteins were similar in size and had no aggregation. Only the purified protein from Process-3 357

showed an additional peak eluting ~1 min earlier, likely, as reported above, a dimer ( Figure  358 4C). Finally, all three proteins were analyzed by DLS to estimate size and dispersity in solution. 359

The estimated sizes of the purified proteins from each process were 29.75, 31.00, and 34.25 360 kDa, respectively ( Figure 4D ). As expected, the protein from Process-3 showed higher 361 polydispersity than the other samples (Supplementary Figure 1) . 362 Impurity assessment in the purified proteins 363 P. pastoris HCP was assayed by Western blot and quantified by ELISA using a second-364 generation P. pastoris HCP detection kit. When 5 µg unpurified proteins (i.e. FS), as well as 365 the purified proteins, were analyzed by SDS-PAGE followed by Coomassie Blue stain and 366

Western blot, we saw that HCP had been effectively removed from all three processes ( Figure  367 5A and B). The HCP content in the purified proteins was calculated as 95.9 ng, 6.8 ng, and 368 44.8 ng per mg of RBD219-N1C1 from Processes 1-3, respectively ( Figure 5C ). All these 369 values were within acceptable limits, 1-100 ng/mg, for biopharmaceuticals [2, 30] . 370 Endotoxin levels measured in the purified proteins were 1.74, 1.48, and 2.10 EU per 371 mg for the purified proteins from Processes 1-3, respectively ( Figure 5D ). These values are 372 significantly lower than the maximum recommended endotoxin level for recombinant subunit 373 vaccines, 20 EU/mL [3] . 374

To evaluate the functionality of the purified proteins from each process, the ability to 376 bind to the human ACE2 receptor was tested in vitro. SARS-CoV-2 uses this human cell 377 surface receptor for cell entry [14] , and here the binding of each protein to ACE2 was quantified 378 by ELISA. All proteins presented similar binding curves to ACE2, with calculated EC50-379 values (for 2 µg/mL purified protein) of 0.037, 0.033, and 0.038 µg/mL ACE2, respectively 380 ( Figure 6 ), suggesting that all three proteins were functionally equivalent. 381 382 Discussion 383

We developed a process suitable for producing a recombinant protein COVID-19 vaccine 384 antigen for clinical testing and transition to industrial manufacture. Fermentations were initially 385 run at the 1 L (for fermentation conditions optimization) and then the 5 L scale (for downstream 386 purification process development). When scaled to 5 L and conditions had only been modified 387 for gas flow and agitation rate to maintain 30% dissolved oxygen, differences in the protein 388 yield were observed. Four subsequent identical 5 L fermentation runs showed high 389 reproducibility with a CV of 8.3%, further emphasizing robustness. 390

Based on our previous experience with SARS-CoV-RBD219-N1 (a prototype vaccine 391 for SARS), a 1.6-to 2.5-fold yield increase was achieved when switching from basal-salt to 392 low-salt medium during the glycerol batch phase in the fermentation process [5] . For SARS-393

CoV2-RBD219-N1C1, a 3.6-fold increase in yield suggests that the salt concentration was a 394 significant factor. In basal-salt medium, the recombinant protein precipitates in the presence of 395 magnesium and calcium phosphates as the pH is adjusted above 5.5. Low-salt medium also 396 precipitates, though to a much lesser extent. The precipitate formation can have adverse effects 397 on the fermentation process as it can lead to an unbalanced nutrient supply, cause cell 398 disruption, and induce secreted proteins to form aggregates [29] . Similar findings had 399 previously been observed with the production of a therapeutic Fc-fusion protein in the 400 fermentation of P. pastoris. When salt supplements were added at induction, the protein yield 401 decreased [23] . 402

Purification optimization produced RBD219-N1C1 at high purity and yield, with a high 403 recovery rate, suitable for scalability for manufacturing. Three purification methods (Processes 404

1-3) were tested and compared using 1 L FS from the identical fermentation runs for rapid 405 development. Process-1 was adapted based on the previous purification method with CoV-RBD219-N1 with slight modification on ammonium salt concentration in HIC. Process-407 1 resulted in 98.3% purity with a 50% overall recovery rate, similar to the 98.5% purity and 408 52% overall recovery shown in SARS-CoV-RBD219-N1 purification ( Figure 3A) [4]. Purity 409 was dramatically increased to >97% after the HIC capture step ( Figure 3A ). Process-1 is 410 suitable to produce the target protein at the laboratory scale but is limited in scale-up due to 411 low binding and process capacities, as well as the long processing time leading to high cost for 412 production. Therefore, two other processes were tested to replace costly HIC and SEC with 413 CEX and AEX, respectively. For biopharmaceuticals, IEX has been favored in chromatography 414 due to its robustness and full scalability [4] . 415

While IEX was tested in the polishing step of Process-2, it was used for both capture 416 and polishing steps in Process-3. In Process-2, AEX showed comparable step recovery, and 417 purity increases to SEC in Process-1 ( Figure 3A and B) . However, a significant improvement 418 in purity by AEX was shown in Process-3 after the capture step by CEX ( Figure 3C ) as the 419 CEX elution pool showed only 83.0% purity. This suggests that AEX not only can successfully 420 replace SEC but also can effectively remove non-specific host proteins. On the contrary, CEX 421 showed comparable step recovery but a lower capability to remove host proteins during the 422 capture step. The purity after the CEX-capture was only 83.0%, which is significantly lower 423 than the purity after HIC-capture (97.6% and 95.2% seen in Processes 1 and 2, respectively) 424 ( Figure 3) . Overall, Process-3 produced the least pure RBD219-N1C1 protein among the three 425 processes tested. 426

Before choosing the best process for purification of RBD219-N1C1, the purified 427 proteins were characterized for their quality based on size, specificity, and impurity. The 428 integrity assessment of the purified proteins was performed by SDS-PAGE. Coomassie-stained 429 gels showed a single band at ~25 kDa that was recognized by a SARS-CoV-2 spike protein-430 specific antibody ( Figure 4A and B). In addition, for Process-3, the western blot indicated the 431 presence of an additional band speculated to be a dimer ( Figure 4B ); this same product was 432 also seen by SEC-HPLC ( Figure 4C ). Although no difference in size was seen among the 433 purified proteins from the three processes by SDS-PAGE ( Figure 4A Figure 5C ). The higher HCP 443 content found in the purified protein from Process-1 was likely due to the presence of HCP 444 with a similar size of RBD219-N1C1, which further suggested that SEC might not be an ideal 445 purification step. No significant difference in endotoxin level was measured in the purified 446 protein from three processes ( Figure 5D ), albeit all protein preparations contained less than the 447 maximally allowed endotoxin levels. Finally, the functionality of the purified proteins from 448 three processes tested by in vitro ACE2 binding assay showed that all three proteins showed 449 similar binding to recombinant human ACE2 receptor ( Figure 6) . 450

In summary, after comparing yield, purity, and recovery after each purification, we 451 conclude that HIC for capture due to its superior capability to remove non-specific host proteins 452 and produce protein with >95% purity, and AEX for polishing due to its low cost and full 453 scalability (Process-2) are best suited to produce RBD219-N1C1. In addition, comparison for 454 the integrity, dimer content, HCP contents, and endotoxin level in purified protein supported 455 the Process-2 generates quality proteins similar to Process-1 but significantly better than 456

Process-3 and, hence, is a more ideal process for upscaling. 457 P. pastoris is widely used to produce recombinant proteins for clinical and commercial 458 use. The P. pastoris system is licensed to more than 300 companies in the biotechnology, Funds. We also would like to thank PATH Center for Vaccine Innovation and Access 482 (Seattle, WA, USA) for their guidance as well as technical and intellectual support. 483 

Recombinant protein subunit vaccine synthesis in microbes: a role for 486 yeast?

The future of host cell protein (HCP) 488 identification during process development and manufacturing linked to a risk-based 489 management for their control

Acceptable levels of endotoxin in vaccine formulations during 492 preclinical research

Optimization of the Production Process and Characterization of the Yeast-Expressed 497 SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine 498

Yeast-expressed 502 recombinant protein of the receptor-binding domain in SARS-CoV spike protein with 503 deglycosylated forms as a SARS vaccine candidate

Process Characterization and Biophysical Analysis

Expressed Phlebotomus papatasi Salivary Protein (PpSP15) as a Leishmania Vaccine 508

CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated with Alum 513 Induces Protective Immunity and Reduces Immune Enhancement

Cloning, Expression and Biophysical Characterization 518 of a Yeast-expressed Recombinant SARS-CoV-2 Receptor Binding Domain COVID-519 19 Vaccine Candidate

COVID-19 vaccine tracker

Biological E's novel Covid-19 vaccine of SARS-CoV-2 for protection 524 against Covid-19 disease

Biological E. Limited Starts Phase I/II Clinical Trial of its COVID-19

Vaccine Candidate

Prospects for a safe COVID-19 vaccine

Hepatitis B vaccines: WHO position paper

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a 539 Clinically Proven Protease Inhibitor

Developing a low-cost and accessible COVID-19 vaccine 542 for global health

COVID-19 Dashboard by the Center for Systems Science and Engineering at 545

Neutralizing antibodies for the 548 treatment of COVID-19

Endosafe(R) Portable Testing SystemTM for the Rapid Analysis of 552 Biopharmaceutical Samples

Yeast-based vaccines: New perspective in vaccine 554 development and application

Commission Statement on the occasion of the 75th session of the UN General 557 Assembly

Feng Z (2020) Early Transmission Dynamics in 563

of Novel Coronavirus-Infected Pneumonia. The New England journal 564 of medicine

Angiotensin-converting 567 enzyme 2 is a functional receptor for the SARS coronavirus

Enhancing the production of Fc fusion protein in 570 fed-batch fermentation of Pichia pastoris by design of experiments

Outbreak of pneumonia of unknown etiology in 573

The mystery and the miracle

Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine 579 Stimulates Virus Neutralizing Antibodies and T-cell Immunity in Mice

Pichia pastoris expression 582 system: a potential candidate to express protein in industrial and biopharmaceutical 583 domains

Structural basis of receptor recognition by SARS-CoV-2

Structural basis for the recognition 588 of SARS-CoV-2 by full-length human ACE2

Glycerophosphate as a phosphorus source in a 591 defined medium for Pichia pastoris fermentation

Host cell protein testing by ELISAs and the use of 595 orthogonal methods

Supplementary Figure 1. Dynamic light scattering results of the purified proteins by Process-638

Measured Stokes radii, polydispersity (PD), and 639 molecular weight (Mw) are shown as an average ± SD from four independent measurements